NYSE · INCY
Healthcare · Biotechnology
$124.37
Down-$3.37 (-2.64%)
Updated Aug 30, 2026, 8:20 AM
SID Score
7.2/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
INCY closed at $124.37 after 20 trading sessions, up 5.02% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $127.74 | $127.74 | $123.08 | $124.37 | 1.22M |
| Aug 27, 2026 | $128.13 | $128.20 | $126.06 | $127.74 | 700.68K |
| Aug 26, 2026 | $129.18 | $129.535 | $127.7701 | $128.12 | 800.28K |
| Aug 25, 2026 | $128.975 | $130.80 | $127.50 | $129.72 | 1.16M |
| Aug 24, 2026 | $127.47 | $128.36 | $126.31 | $127.98 | 799.61K |
| Aug 21, 2026 | $126.45 | $129.92 | $125.60 | $127.81 | 1.37M |
| Aug 20, 2026 | $127.10 | $129.80 | $126.71 | $127.22 | 1.21M |
| Aug 19, 2026 | $125.00 | $129.56 | $124.595 | $128.47 | 1.59M |
| Aug 18, 2026 | $124.29 | $124.74 | $123.23 | $123.47 | 1.19M |
| Aug 17, 2026 | $120.16 | $124.06 | $119.64 | $123.50 | 2.04M |
| Aug 14, 2026 | $119.15 | $120.435 | $117.56 | $120.16 | 785.83K |
| Aug 13, 2026 | $122.23 | $122.23 | $119.71 | $120.52 | 829.46K |
| Aug 12, 2026 | $119.54 | $121.57 | $118.88 | $120.77 | 1.06M |
| Aug 11, 2026 | $121.13 | $122.28 | $120.0588 | $121.07 | 1.08M |
| Aug 10, 2026 | $120.56 | $122.688 | $120.50 | $121.55 | 1.35M |
| Aug 7, 2026 | $118.56 | $120.88 | $117.38 | $120.56 | 1.54M |
| Aug 6, 2026 | $119.80 | $120.29 | $115.77 | $118.38 | 2.39M |
| Aug 5, 2026 | $123.99 | $124.57 | $119.52 | $119.80 | 1.8M |
| Aug 4, 2026 | $119.08 | $120.93 | $117.00 | $120.60 | 2.08M |
| Aug 3, 2026 | $120.22 | $121.37 | $118.02 | $118.43 | 1.42M |
The latest Smart Investors Daily articles mentioning INCY.
INCY research
Company profile and research snapshot.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20, 2026 | Canaccord Genuity | Buy | — |
| Aug 20, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 17, 2026 | Piper Sandler | Overweight | — |
| Aug 4, 2026 | Mizuho | Outperform | — |
| Aug 3, 2026 | Leerink Partners | Outperform | — |
No generated briefing is available yet.
ChartMill · Aug 27, 2026
INCYTE (INCY) passes Minervini Trend Template & High Growth screen with strong earnings, sales, RS 93. Setup score 6/10 means wait for better entry.
Yahoo · Aug 24, 2026
SYRE expands into HS with SPY772, testing whether dual-pathway inhibition can strengthen outcomes in SKYLIGHT.
SeekingAlpha · Aug 23, 2026
Prelude Therapeutics has rebounded 500% in 12 months after a $60M option deal with Incyte for its JAK2 inhibitor program. Read why PRLD stock is a Hold.
SeekingAlpha · Aug 22, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning INCY.
